O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma

Journal of Nuclear Medicine

Volumn 52, Issue 6, 2011, Pages 856-864

  Hutterer, Markus ^a,b   Nowosielski, Martha ^a   Putzer, Daniel ^a   Waitz, Dietmar ^a   Tinkhauser, Gerd ^a   Kostron, Herwig ^a   Muigg, Armin ^a   Virgolini, Irene J ^a   Staffen, Wolfgang ^b   Trinka, Eugen ^b   Gotwald, Thaddäus ^a   Jacobs, Andreas H ^c   Stockhammer, Guenther ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

18F FET PET response assessment; Antiangiogenic treatment; MRI response criteria; Recurrent high grade glioma

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DEXAMETHASONE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; IRINOTECAN; LOMUSTINE; O (2 FLUOROETHYL) TYROSINE FLUORODEOXYGLUCOSE F 18; PROCARBAZINE; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE; CAMPTOTHECIN; DIAGNOSTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; O (2 FLUOROETHYL)TYROSINE; O-(2-FLUOROETHYL)TYROSINE; RADIOPHARMACEUTICAL AGENT; TYROSINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; FEMALE; GLIOMA; HUMAN; INTERMETHOD COMPARISON; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; TUMOR VOLUME; ASTROCYTOMA; BRAIN TUMOR; CASE REPORT; DISEASE FREE SURVIVAL; ECHOGRAPHY; IMAGE PROCESSING; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEUROLOGIC DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; SCINTISCANNING; SURVIVAL; TREATMENT FAILURE;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ASTROCYTOMA; BRAIN NEOPLASMS; CAMPTOTHECIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE; TYROSINE;

EID: 79958148395     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.086645     Document Type: Article

References (30)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
2. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845-848.
3. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685-693. (Pubitemid 36749217)
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
5. Vredenburgh JJ, Desjardins A, Herndon JE Jr., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722-4729. (Pubitemid 350086473)
6. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. 2009;22:633-638.
7. van den Bent MJ VM, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol. 2009;27:2905-2908.
8. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963-1972.
9. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432-445. (Pubitemid 32207394)
10. Floeth FW, Pauleit D, Sabel M, et al. 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med. 2006;47:776-782. (Pubitemid 46768440)
11. 18F]fluoroethyl)-L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging. 2004;31:1464-1470.
12. Yushkevich PA, Piven J, Hazlett HC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006;31:1116-1128. (Pubitemid 43851334)
13. 18F]fluoroethyl) -L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678-687.
14. 18F-FDG PET in brain tumors. Nucl Med Biol. 2009;36:779-787.
15. Fischman AJ, Strauss HW. Clinical PET: a modest proposal. J Nucl Med. 1991;32:2351-2355.
16. HERMES. Hermes MultiModality: Advancing the Art of Fusion 2010. Available at: http://www.hermesmedical.com/. Accessed May 4, 2011.
17. Swets JA. ROC analysis applied to the evaluation of medical imaging techniques. Invest Radiol. 1979;14:109-121. (Pubitemid 9182004)
18. 18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714-4721.
19. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-1782.
20. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer. 2008;44:946-953.
21. Nowosielski M, Recheis W, Goebel G, et al. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology. 2011;53:291-302.
22. Dhermain FG, Hau P, Lanfermann H, Jacobs AH, van den Bent MJ. Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. Lancet Neurol. 2010;9:906-920.
23. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR. 2006;27:859-867. (Pubitemid 44897737)
24. Sawlani RN, Raizer J, Horowitz SW, et al. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging - pilot study. Radiology. 2010;255:622-628.
25. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR. 2009;30:552-558.
26. Jain R, Scarpace LM, Ellika S, et al. Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker. J Neurooncol. 2010;96:423-431.
27. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66:1258-1260. (Pubitemid 43739717)
28. Vredenburgh JJ, Desjardins A, Herndon JE Jr., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253-1259. (Pubitemid 46424067)
29. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83-95. (Pubitemid 46075199)
30. de Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010;12:233-242.